{"gene":"GPER1","run_date":"2026-06-10T01:55:21","timeline":{"discoveries":[{"year":2012,"finding":"GPER-1 (GPR30) is a Gs-coupled heptahelical transmembrane receptor that stimulates adenylyl cyclase and promotes Gβγ-subunit protein-dependent release of membrane-tethered heparan-bound epidermal growth factor (HB-EGF); selective agonists/antagonists discriminate it from nuclear ERα and ERβ.","method":"Pharmacological agonist/antagonist studies, receptor knockdown, cAMP assays","journal":"Endocrinology","confidence":"High","confidence_rationale":"Tier 2 / Strong — pharmacological dissection replicated across multiple labs, receptor knockdown controls, widely cited consensus mechanism","pmids":["22495674"],"is_preprint":false},{"year":2017,"finding":"GPR30/GPER1 increases ERK1/2 activity via two distinct Gi/o-mediated mechanisms: (1) a PDZ motif-dependent constitutive mechanism requiring AKAP5, and (2) a PDZ-independent G-1-stimulated mechanism; the PDZ interaction with SAP97 and AKAP5 anchors the receptor at the plasma membrane and also mediates a constitutive decrease in cAMP independently of Gi/o.","method":"PDZ motif deletion mutants, AKAP5 knockdown, pertussis toxin (Gi/o inhibitor), PI3K inhibitor wortmannin, EGFR inhibitor AG1478, phosphatase inhibitors FK506 and okadaic acid; ERK1/2 activity assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — multiple orthogonal pharmacological and genetic approaches (mutagenesis of PDZ motif, specific knockdowns, kinase inhibitors) in one rigorous study","pmids":["28450397"],"is_preprint":false},{"year":2022,"finding":"GPR30/GPER1 couples to the canonical Gq-phospholipase C pathway, activating protein kinase C and ERK; the receptor undergoes internalization upon continuous agonist exposure. Cell-line-dependent localization (plasma membrane in HEK293 and MCF-7; endomembrane retention in Cos-7 and HeLa) explains conflicting signaling reports. Classical agonists (17β-estradiol, 4-OHT, G-1) did not reproduce cAMP increases in this system.","method":"Multiplexed GPCR Ca2+ screen, stable/transient overexpression in HEK293 and multiple cell lines, Gq inhibitor YM-254890, PLC and PKC pathway analysis, receptor internalization assay, fluorescent fusion protein imaging","journal":"Molecular pharmacology","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — rigorous unbiased GPCR screen with orthogonal pathway characterization (Ca2+, Gq inhibitor, PKC, ERK, internalization) in single study with multiple cell lines","pmids":["36400433"],"is_preprint":false},{"year":2019,"finding":"GPER1 activates PRKACA (protein kinase A catalytic subunit alpha), which phosphorylates MORC2 at threonine 582; phosphorylated MORC2 reduces its interaction with HSPA8 and LAMP2A (chaperone-mediated autophagy components), protecting MORC2 from lysosomal degradation. A phosphorylation-lacking MORC2 T582A mutant cannot restore antiestrogen resistance.","method":"Co-immunoprecipitation, phosphorylation-site mutagenesis (T582A), CMA pathway inhibition, GPER1-dependent PRKACA activation assays, knockdown and rescue experiments in breast cancer cells","journal":"Autophagy","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — mutagenesis of phosphorylation site, co-IP, pathway dissection with multiple complementary approaches in single rigorous study","pmids":["32401166"],"is_preprint":false},{"year":2015,"finding":"GPER1 activation triggers BDNF release in hippocampal field CA3, leading to transient stimulation of Arc protein translation and GluA1-containing AMPA receptor internalization; mGluR-dependent LTD at the mossy fiber pathway requires prior GPER1 stimulation and is associated with ubiquitin-proteasome-mediated degradation of GluA1.","method":"Selective GPER1 agonist G1, BDNF release assay, Arc translation assay, GluA1 internalization assay, proteasome inhibition, live hippocampal slice electrophysiology","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — multiple orthogonal biochemical and electrophysiological methods in single rigorous study establishing novel synaptic mechanism","pmids":["26391661"],"is_preprint":false},{"year":2014,"finding":"GPER-1 stimulation with selective agonist G-1 increases aldosterone synthase expression and aldosterone production via protein kinase A signaling in adrenocortical HAC15 cells; silencing of ERβ unmasks this stimulatory GPER-1 effect, while silencing of GPER-1 blunts aldosterone synthase expression and blocks E2-stimulated aldosterone production under ERβ blockade.","method":"GPER-1 agonist G-1, GPER-1 antagonist G-15, selective PKA inhibitor, gene silencing (ERβ and GPER-1 siRNA), aldosterone synthase expression assays, aldosterone production measurement","journal":"Endocrinology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — pharmacological agonism/antagonism combined with gene silencing and rescue, multiple complementary readouts in single study","pmids":["25167221"],"is_preprint":false},{"year":2020,"finding":"GPER1 negatively regulates ERα protein levels by upregulating the Cullin3-based E3 ubiquitin ligase adaptor SPOP, which promotes ubiquitin-proteasome-dependent degradation of ERα; SPOP depletion abrogates GPER1-induced ERα ubiquitination and degradation. GPER1 activation inhibits E2-induced ERα+ breast cancer cell proliferation in vitro and tumor growth in vivo.","method":"Co-immunoprecipitation, ubiquitination assay, SPOP knockdown rescue experiments, proteasome inhibition, in vivo xenograft model","journal":"Cancer letters","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — direct ubiquitination assay, Co-IP, genetic knockdown rescue, and in vivo validation in single rigorous study","pmids":["33069770"],"is_preprint":false},{"year":2014,"finding":"GPER-1 promotes fibronectin (FN) matrix assembly and release of HB-EGF; GPER-1 stimulation forms integrin α5β1-Shc adaptor protein complexes at fibrillar adhesions. Shc mutant Y317F (lacking primary tyrosyl phosphorylation site) disrupts E2-induced focal adhesion and actin stress fiber formation and abolishes E2-enhanced haptotaxis and FN-dependent anchorage-independent growth.","method":"Stable Shc Y317F mutant expression, focal adhesion and actin stress fiber imaging, haptotaxis assays, hanging-drop anchorage-independent growth assay, immunoprecipitation of integrin α5β1-Shc complexes","journal":"Hormones & cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — phosphorylation-site mutagenesis with functional readouts, but single lab","pmids":["25096985"],"is_preprint":false},{"year":2017,"finding":"Estrogen-induced angiogenesis via GPER1 requires upregulation of the glycolytic enzyme PFKFB3 in HUVECs; GPER1 antagonist G-15 or GPER1 siRNA abolishes E2-induced PFKFB3 expression, and PFKFB3 inhibition blocks GPER1-mediated HUVEC migration.","method":"GPER1-selective agonist G-1, GPER1 antagonist G-15, GPER1 siRNA, PFKFB3 inhibitor, HUVEC migration and angiogenesis assays, PFKFB3 expression measurement","journal":"The Journal of pharmacology and experimental therapeutics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological and siRNA approaches with functional readouts, single lab","pmids":["28348059"],"is_preprint":false},{"year":2013,"finding":"GPER-1-mediated vasoconstriction in isolated rat kidney involves ROCK, PKC, p38 MAPK, p42/44 MAPK, tyrosine kinase, EGF receptor kinase and voltage-operated Ca2+ channels but not JNK or PI3K; the effect is endothelium-independent and blocked by GPER-1 antagonist G15.","method":"Isolated perfused rat kidney, selective kinase inhibitors (Y-27632 for ROCK, PD98059 for ERK, SB203580 for p38, GF109203X for PKC, genistein for tyrosine kinase, AG-1478 for EGFR, nifedipine for Ca2+ channels), endothelium removal with saponin, Western blot for GPER-1 expression","journal":"European journal of pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple pathway inhibitors in intact organ preparation, single lab","pmids":["23376418"],"is_preprint":false},{"year":2013,"finding":"GPER-1 agonist G1 induces endothelium-dependent vasorelaxation via Src-mediated transactivation of the EGF receptor, followed by Akt pathway activation; this is blocked by NOS inhibitor L-NAME, EGFR blockers AG1478 and DAPH, Src inhibitor, and Akt inhibitor VIII, but not by classical ER antagonists, PI3K inhibitors or ERK inhibitor.","method":"Rat aortic ring organ bath experiments, selective inhibitors of NOS, EGFR, Src, Akt, PI3K, ERK; GPER-1 antagonist HB-EGF","journal":"The Journal of pharmacy and pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological pathway dissection with multiple inhibitors in ex vivo tissue, single lab","pmids":["24028616"],"is_preprint":false},{"year":2013,"finding":"GPER-1 agonist G1 reduces vascular smooth muscle cell Ca2+ spike activity by blocking voltage-sensitive L-type Ca2+ channels; the effect is blocked by GPER-1 antagonist G15, supporting a GPER-1-dependent mechanism for blood pressure regulation.","method":"Ca2+ imaging in A7r5 smooth muscle cells, L-type Ca2+ channel blocker nifedipine, GPER-1 antagonist G15, thromboxane A2 analogue stimulation, KCl-evoked Ca2+ measurement","journal":"Journal of vascular research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — live-cell Ca2+ imaging with pharmacological controls in defined cell line, single lab","pmids":["24080531"],"is_preprint":false},{"year":2013,"finding":"GPER1 activation via G1 upregulates ROCK-2 expression in rat coronary vascular endothelial cells through GPER1 and EGFR transactivation; the effect requires Gi/o protein signaling (blocked by pertussis toxin), EGFR kinase (blocked by AG-1478), and de novo transcription (blocked by actinomycin-D), but is not replicated by ERα or ERβ selective agonists.","method":"Western blot for ROCK-2 and GPER1 in primary rat coronary vascular endothelial cells, GPER1 agonist G1, GPER1 antagonist G-15, pertussis toxin (Gi/o inhibitor), AG-1478 (EGFR blocker), actinomycin-D (transcription inhibitor), ERα/ERβ agonists","journal":"Endocrine regulations","confidence":"Low","confidence_rationale":"Tier 3 / Weak — pharmacological approach in primary cells without genetic confirmation, single lab, limited mechanistic resolution","pmids":["23641788"],"is_preprint":false},{"year":2014,"finding":"GPER1 stimulation of 5-HT1A receptor desensitization in the rat hypothalamic paraventricular nucleus involves altered isoform expression and posttranslational modification of RGSz1; high-molecular-weight SUMOylated and glycosylated RGSz1 is increased by G-1 treatment and localizes to the detergent-resistant membrane microdomain, where it can reduce Gαz activity and uncouple 5-HT1AR signaling.","method":"Selective GPER1 agonist G-1, subcellular fractionation (detergent-resistant microdomains), Western blot for RGSz1 isoforms, SUMO and glycosylation analysis, oxytocin/ACTH hormonal response assays in vivo","journal":"Neuroendocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — subcellular fractionation and PTM characterization with in vivo hormonal readout, single lab","pmids":["25402859"],"is_preprint":false},{"year":2021,"finding":"GPER1 activation during pregnancy suppresses interferon (IFN) signaling preferentially in reproductive and fetal tissues; GPER1 inactivation in mice caused fetal demise and halted fetal development only in the context of maternal inflammation, establishing GPER1 as a necessary regulator of type I IFN signaling that protects fetal health.","method":"GPER1 knockout mice, maternal inflammation models, IFN signaling assays in fetal vs. maternal tissues, tissue-specific comparison of IFN suppression","journal":"Science (New York, N.Y.)","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout with specific phenotypic readout (fetal demise in inflammatory context), published in high-impact journal with rigorous controls","pmids":["33446553"],"is_preprint":false},{"year":2015,"finding":"GPER1 activation by 17β-estradiol inhibits constitutively active ERK1/2 in granulosa cell tumor cells and decreases migration and matrix invasion through non-genomic mechanisms; this anti-metastatic effect is mediated specifically by GPER1 signaling as demonstrated by pharmacological and RNA silencing approaches.","method":"Pharmacological GPER1 inhibitors, siRNA silencing of GPER1, ERK1/2 phosphorylation assays, migration and matrix invasion assays in KGN and COV434 cells","journal":"Carcinogenesis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological and siRNA approaches with functional readouts, single lab","pmids":["25823895"],"is_preprint":false},{"year":2014,"finding":"GPER-1 activation by E2 or selective agonist G-1 downregulates testosterone production in LH-stimulated isolated rat Leydig cells and in human testicular tissue by 20-30%; this is a GPER-1-specific effect as the testis lacks ERα.","method":"Isolated rat Leydig cells and human testis tissue, selective GPER-1 agonist G-1, ERα/β antagonist ICI 182,780, radioimmunoassay of testosterone, qRT-PCR and immunofluorescence for GPER-1 localization, MTS cell viability assay","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — primary cells and human tissue with pharmacological dissection, single lab","pmids":["24736568"],"is_preprint":false},{"year":2019,"finding":"Autocrine motility factor (AMF) physically binds to GPER-1, and the AMF-GPER-1 complex translocates from the plasma membrane to the cytoplasm; this interaction triggers PI3K/AKT signaling to promote endometrial cancer cell growth.","method":"Yeast two-hybrid assay, co-immunoprecipitation, immunofluorescence, iTRAQ proteomic analysis of downstream pathway, xenograft mouse model","journal":"Cell communication and signaling : CCS","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP confirmed by yeast two-hybrid and immunofluorescence, with pathway identification by proteomics and in vivo validation","pmids":["30836961"],"is_preprint":false},{"year":2015,"finding":"GPER1 mediates estradiol-induced enhancement of hippocampal CA3-CA1 synaptic transmission; G1 pretreatment occludes EB-mediated enhancement, GPER1 antagonist G15 blocks EB-induced synaptic enhancement, and the effect requires ERK activation regardless of ERα or ERβ genotype.","method":"Extracellular field potential recordings in hippocampal slices from WT, ERαKO, and ERβKO mice; selective GPER1 agonist G1, antagonist G15, ERK inhibitor, occlusion experiments","journal":"Hippocampus","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — electrophysiological recordings with genetic knockout controls and pharmacological dissection, single lab","pmids":["25980457"],"is_preprint":false},{"year":2016,"finding":"In embryonic hippocampal mHippoE-18 cells, GPER1 activation by 17β-estradiol, G1, tamoxifen, or ICI 182,780 produces dose-dependent potentiation of forskolin-stimulated cAMP (not observed with ERα or ERβ agonists); however, GPER1-specific antagonists G15 and G36 convert agonist-induced cAMP stimulation into inhibition, while aldosterone mimics the antagonist-induced inhibitory effect — consistent with 'biased antagonism' altering receptor coupling.","method":"cAMP assay in mHippoE-18 cells (endogenous GPER1), selective ER agonists (PPT for ERα, DPN for ERβ), GPER1 antagonists G15 and G36, aldosterone treatment","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — endogenous receptor in neuronal cell line with pharmacological dissection, single lab, functional cAMP readout","pmids":["26998610"],"is_preprint":false},{"year":2014,"finding":"Insulin transactivates the GPER1 promoter and increases GPER1 mRNA and protein expression through the PRKCD/MAPK1/c-Fos/AP1 transduction pathway in leiomyosarcoma cells and breast cancer-associated fibroblasts; GPER1-dependent cell migration triggered by insulin occurs through GPER1 and its target gene CTGF.","method":"GPER1 promoter reporter assay, pharmacological inhibitors of PRKCD and MAPK1, gene silencing, cell migration assays","journal":"Endocrine-related cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter reporter assay with pharmacological and siRNA dissection, multiple cancer cell types, single lab","pmids":["25012984"],"is_preprint":false},{"year":2015,"finding":"In breast cancer cells, 17β-estradiol and GPER1 upregulate ceramide synthases CerS4 and CerS5 via AP-1 transcription factor activation (most likely through dimerization of c-Jun and c-Fos); GPER1 co-transfection enhances CerS2, CerS4, and CerS6 promoter activity.","method":"Luciferase reporter gene assays with CerS promoter constructs, promoter deletion and mutation analysis, co-transfection of GPER1, fulvestrant inhibition","journal":"Biochemical pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter mutagenesis with luciferase reporters and GPER1 overexpression, single lab","pmids":["25451689"],"is_preprint":false},{"year":2015,"finding":"GPER1 activation in MCF-7 breast cancer cells mediates 4-OHT (tamoxifen)-induced IGFBP-1 transcription via CREB; extracellular IGFBP-1 then inhibits IGF-1-dependent PI3K/Akt signaling. GPER1 knockdown abrogates 4-OHT-dependent IGFBP-1 induction.","method":"Conditioned medium transfer experiments, IGFBP-1 mRNA and protein measurement, GPER1 knockdown, CREB knockdown, phospho-Akt assay, neutralizing antibody experiments","journal":"Molecular and cellular endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockdown with multiple molecular readouts, single lab","pmids":["26690777"],"is_preprint":false},{"year":2016,"finding":"GPER-1 activation reduces BBB permeability after global cerebral ischemia by increasing tight junction proteins (occludin and claudin-5) and decreasing VEGF-A expression in the CA1 region.","method":"Intracerebroventricular GPER-1 agonist G1 injection in 4-vessel occlusion rat model, IgG extravasation assay, Western blot for tight junctions and VEGF-A","journal":"Biochemical and biophysical research communications","confidence":"Low","confidence_rationale":"Tier 3 / Weak — pharmacological agonist in vivo with protein expression readouts, no genetic confirmation, single lab","pmids":["27311857"],"is_preprint":false},{"year":2011,"finding":"GPER1 agonist G-1 attenuates endothelial cell proliferation by inhibiting DNA synthesis and accumulating cells in S and G2 phases; GPER1 siRNA prevents G-1-induced attenuation of DNA synthesis, confirming GPER1 dependence. The antiproliferative effect is independent of ERK/MAP kinase.","method":"GPER1 siRNA in bEnd.3 cells, BrdU/DNA synthesis assay, cell cycle analysis, ERK inhibitor PD98059, comparison in COS-7 cells (low GPER1 expression)","journal":"Journal of vascular research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA knockdown confirms GPER1 dependence with clear mechanistic readout, multiple endothelial cell types, single lab","pmids":["21273787"],"is_preprint":false},{"year":2017,"finding":"GPER1 knockdown in gastric cancer cells suppresses proliferation, migration, and invasion by inhibiting PI3K/AKT-mediated EMT; PI3K activator 740Y-P reverses these effects, placing GPER1 upstream of PI3K/AKT in this pathway.","method":"siRNA knockdown of GPER1, PI3K activator rescue experiment, EMT marker expression (E-cadherin, N-cadherin, vimentin), transcription factor analysis (Snail, Slug, Twist1), GPER1 overexpression plasmid","journal":"Frontiers in cell and developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockdown and overexpression with pharmacological rescue, single lab","pmids":["33425895"],"is_preprint":false},{"year":2016,"finding":"GPER1 mediates neuroprotection against oxygen-glucose deprivation in hippocampal neurons via PI3K/Akt-dependent Ask1 inhibition; GPER1 knockdown diminishes E2/E2-BSA protection, while GPER1 overexpression potentiates it.","method":"GPER1 knockdown and overexpression in primary hippocampal neurons, OGD model, membrane-impermeable E2-BSA, PI3K inhibition, Ask1 phosphorylation assay","journal":"Neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic gain and loss of function with pathway identification, single lab","pmids":["27113328"],"is_preprint":false},{"year":2020,"finding":"ERα36 and GPER1 physically interact (by Co-IP) and collaborate to inhibit LPS/TLR4-induced NF-κB activity; GPER1 directly interacts with the p65 component of NF-κB in breast cancer cells. ERα36 knockdown partially inhibits this anti-inflammatory effect in the presence of ERα66.","method":"Co-immunoprecipitation of ERα36 with GPER1 and with NF-κB p65, siRNA knockdown, NF-κB reporter assay, IL-6/TNFα expression","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP with functional siRNA knockdown, single lab","pmids":["34299224"],"is_preprint":false},{"year":2015,"finding":"In human monocytes, GPER1 physically interacts with ERα36 splice variant; ligand-activated ERα36 directly interacts with the p65 component of NF-κB in the nucleus to inhibit IL-6 expression. GPER1 acts as a co-regulator—its inhibition blocks estrogen's anti-IL-6 effect, but GPER1 activation alone does not mimic it.","method":"Co-immunoprecipitation of GPER1 with ERα36, nuclear interaction of ERα36 with p65 NF-κB, GPER1/ERα36 selective inhibitors, IL-6 measurement, NF-κB reporter assay in primary human monocytes","journal":"Journal of leukocyte biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP in primary human cells with functional pharmacological dissection, single lab","pmids":["26394816"],"is_preprint":false},{"year":2019,"finding":"GPER1 agonist G-1 activates BDNF/TrkB signaling in the hippocampus to improve synaptic and mitochondrial function in SPS (PTSD model) mice; the effect is blocked by both GPER1 antagonist G15 and TrkB inhibitor ANA-12, placing GPER1 upstream of BDNF/TrkB.","method":"Western blot and immunofluorescence for GPER1, BDNF/TrkB pathway analysis, electrophysiological LFP recordings, synaptic and mitochondrial protein expression, GPER1 agonist/antagonist in SPS mouse model","journal":"CNS neuroscience & therapeutics","confidence":"Low","confidence_rationale":"Tier 3 / Weak — pharmacological agonism/antagonism approach with pathway analysis, single lab, no genetic confirmation","pmids":["38992889"],"is_preprint":false},{"year":2023,"finding":"In mucopolysaccharidosis I cells, GPER1 forms aggregates that disappear when cells are treated with the deficient enzyme (which degrades glycosaminoglycans), suggesting GPER1 aggregation is caused by interaction with accumulated GAGs rather than altered protein expression.","method":"Immunofluorescence for GPER1 aggregates, enzyme replacement treatment, transcriptomic analysis, GPER1 gene/protein expression comparison between aggregate-positive and negative conditions","journal":"European journal of cell biology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — immunofluorescence with enzyme treatment, indirect evidence for GAG-GPER1 interaction, single lab","pmids":["35537249"],"is_preprint":false},{"year":2023,"finding":"GPER1 activation in macrophages inhibits M1 and M2 macrophage polarization via downregulation of MAPK pathways, reducing renal fibrosis in UUO mice; Gper1 deletion in male UUO mice accelerated fibrosis and increased inflammation.","method":"GPER1 agonist G-1 in OVX/male UUO mice, Gper1 knockout mice, RNA-sequencing, immunoblotting for MAPK, macrophage co-culture with tubular epithelial cells and fibroblasts","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockout and pharmacological agonism with RNA-seq pathway analysis, single lab","pmids":["38086848"],"is_preprint":false},{"year":2023,"finding":"GPER1 activation upregulates the miR-29b oncosuppressor network and blunts an established miR-29b-Sp1 feedback loop in multiple myeloma cells, contributing to anti-tumor activity.","method":"GPER1 agonist G-1 in MM cells, miR-29b expression analysis, Sp1 pathway analysis, apoptosis assays, in vivo xenograft models","journal":"Cells","confidence":"Low","confidence_rationale":"Tier 3 / Weak — pharmacological approach with miRNA pathway analysis, single lab, mechanistic depth limited","pmids":["37759449"],"is_preprint":false},{"year":2023,"finding":"In the placenta, E2 enhances melatonin synthetase AANAT expression and melatonin production in primary human trophoblast cells through the GPER1-PKA-CREB signaling pathway.","method":"Primary human trophoblast cells, GPER1 pharmacological agonism, PKA and CREB pathway analysis, AANAT expression and melatonin production assays","journal":"Journal of pineal research","confidence":"Low","confidence_rationale":"Tier 3 / Weak — pharmacological approach in primary cells, single lab, no genetic confirmation","pmids":["37746893"],"is_preprint":false},{"year":2022,"finding":"Bisphenol S (BPS)-induced upregulation of Agrp in hypothalamic neurons is prevented by GPER1 inhibitor G15, establishing that BPS acts through GPER1 to induce Agrp expression independently of Atf3 and Klf4 upregulation.","method":"GPER1 inhibitor G15 in immortalized murine hypothalamic cell lines (mHypoE-41, mHypoA-59), Agrp mRNA measurement, transcription factor expression profiling","journal":"Molecular and cellular endocrinology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — pharmacological inhibition approach only, no genetic confirmation, single lab","pmids":["35569583"],"is_preprint":false},{"year":2019,"finding":"GPER1 agonist G-1 activates GPER1/cAMP-dependent Erk/MAPK cascade to upregulate Runx2 osteogenic transcription factor in osteoblasts; G15 (GPER1 antagonist) abolishes prunetin-induced increases in cAMP, osteoblast proliferation, and differentiation.","method":"Primary rat osteoblast cultures, HEK293T cells, selective GPER1 agonist G-1, antagonist G15, cAMP measurement, ERK/MAPK inhibition, Runx2 expression analysis, in vivo drill-hole injury rat model","journal":"The Journal of nutritional biochemistry","confidence":"Low","confidence_rationale":"Tier 3 / Weak — pharmacological agonism/antagonism, single lab, no genetic confirmation of GPER1 specificity","pmids":["26345541"],"is_preprint":false}],"current_model":"GPER1 (GPR30) is a seven-transmembrane G protein-coupled estrogen receptor that, upon estrogen binding, canonically couples to Gs to stimulate adenylyl cyclase/cAMP, activates Gβγ-dependent transactivation of the EGFR (releasing HB-EGF), and engages Gi/o via a PDZ-motif/AKAP5-dependent constitutive mechanism and a PDZ-independent ligand-stimulated mechanism to increase ERK1/2 activity; a parallel screen study established Gq-phospholipase C-PKC coupling as an additional canonical pathway whose prominence depends on cell-type-specific plasma membrane localization versus endomembrane retention. Downstream, GPER1 signals through PI3K/Akt, MAPK/ERK, and PKA-CREB cascades to regulate diverse processes including synaptic plasticity (via BDNF release and AMPA receptor internalization in hippocampus), vascular tone (via Ca2+ channel inhibition in smooth muscle), immune/inflammatory suppression (by co-regulating NF-κB with ERα36), ERα protein stability (by upregulating the E3 ubiquitin ligase adaptor SPOP), MORC2 stability (via PRKACA-dependent phosphorylation that blocks chaperone-mediated autophagy), type I interferon signaling suppression in fetal tissues, and aldosterone synthesis (via PKA signaling in adrenocortical cells)."},"narrative":{"mechanistic_narrative":"GPER1 (GPR30) is a seven-transmembrane G protein-coupled estrogen receptor that translates estrogen binding into rapid non-genomic signaling to regulate vascular, neuronal, reproductive, immune, and oncogenic processes [PMID:22495674, PMID:33446553]. As a Gs-coupled receptor it stimulates adenylyl cyclase and drives Gβγ-dependent release of membrane-tethered HB-EGF, transactivating the EGFR [PMID:22495674]; in parallel it engages Gi/o to increase ERK1/2 activity through both a constitutive PDZ-motif/AKAP5-anchored mechanism and a ligand-stimulated PDZ-independent mechanism, with the PDZ interaction (SAP97, AKAP5) anchoring the receptor at the plasma membrane and constitutively lowering cAMP [PMID:28450397], and it couples to a Gq–phospholipase C–PKC–ERK cascade whose prominence tracks with cell-type-specific plasma-membrane versus endomembrane localization [PMID:36400433]. Downstream, GPER1 signals through PKA, PI3K/Akt, and MAPK/ERK to diverse effectors: it activates PRKACA to phosphorylate MORC2 at Thr582, blocking its chaperone-mediated autophagic degradation [PMID:32401166], and upregulates the Cullin3 E3 ligase adaptor SPOP to drive ubiquitin-proteasomal degradation of ERα, restraining estrogen-driven breast cancer growth [PMID:33069770]. In the nervous system it triggers hippocampal BDNF release with Arc translation and AMPA-receptor (GluA1) internalization underlying synaptic plasticity [PMID:26391661] and mediates estradiol-induced potentiation of CA3–CA1 transmission via ERK [PMID:25980457]. In the vasculature it controls tone through EGFR/Src/Akt-dependent vasorelaxation and L-type Ca2+ channel inhibition in smooth muscle [PMID:24028616, PMID:24080531]. GPER1 also suppresses inflammatory signaling—co-regulating NF-κB with ERα36 and interacting with p65 [PMID:34299224, PMID:26394816]—and, genetically, is a required suppressor of type I interferon signaling protecting fetal development under maternal inflammation [PMID:33446553]. Additional aldosterone, angiogenic, and matrix-assembly roles connect the receptor to adrenocortical PKA signaling, glycolytic PFKFB3, and integrin α5β1–Shc adhesion complexes [PMID:25167221, PMID:28348059, PMID:25096985].","teleology":[{"year":2012,"claim":"Established that GPER1 is a bona fide membrane estrogen receptor pharmacologically distinct from nuclear ERs, defining its core Gs/cAMP and EGFR-transactivation output.","evidence":"Pharmacological agonist/antagonist dissection, receptor knockdown, and cAMP assays","pmids":["22495674"],"confidence":"High","gaps":["Did not resolve which G proteins dominate in different cell types","No structural basis for ligand discrimination"]},{"year":2017,"claim":"Resolved how GPER1 controls ERK1/2, distinguishing a constitutive PDZ/AKAP5-anchored route from a ligand-stimulated PDZ-independent route and linking receptor anchoring to cAMP regulation.","evidence":"PDZ-motif deletion mutants, AKAP5 knockdown, pertussis toxin and kinase/phosphatase inhibitors with ERK1/2 assays","pmids":["28450397"],"confidence":"High","gaps":["Physiological relevance of constitutive vs. ligand-driven signaling in vivo not defined","Whether the two mechanisms act in the same cells unclear"]},{"year":2022,"claim":"Demonstrated Gq–PLC–PKC–ERK coupling and showed that subcellular localization (plasma membrane vs. endomembrane) reconciles contradictory signaling reports across cell lines.","evidence":"Multiplexed GPCR Ca2+ screen, Gq inhibitor YM-254890, internalization and localization imaging across multiple cell lines","pmids":["36400433"],"confidence":"High","gaps":["Failure to reproduce cAMP increases leaves Gs coupling context-dependent and unresolved","Determinants of plasma-membrane versus endomembrane targeting unidentified"]},{"year":2015,"claim":"Connected GPER1 to synaptic plasticity by showing it drives BDNF release, Arc translation, and AMPA receptor internalization, providing a mechanism for estrogen modulation of hippocampal function.","evidence":"GPER1 agonist G1, BDNF/Arc/GluA1 assays, proteasome inhibition, and hippocampal slice electrophysiology","pmids":["26391661","25980457"],"confidence":"High","gaps":["Endogenous estrogen ligand source in this circuit not established","Receptor localization (pre- vs. postsynaptic) not defined"]},{"year":2019,"claim":"Identified a GPER1→PRKACA→MORC2 phosphorylation axis that stabilizes MORC2 by blocking chaperone-mediated autophagy, linking the receptor to antiestrogen resistance.","evidence":"Co-IP, T582A phospho-site mutagenesis, CMA pathway inhibition, and knockdown/rescue in breast cancer cells","pmids":["32401166"],"confidence":"High","gaps":["Direct kinase–substrate contact not structurally resolved","Generality beyond breast cancer cells untested"]},{"year":2020,"claim":"Showed GPER1 negatively regulates ERα protein via SPOP-mediated ubiquitin-proteasomal degradation, establishing a tumor-suppressive cross-talk with the nuclear estrogen pathway.","evidence":"Co-IP, ubiquitination assay, SPOP knockdown rescue, proteasome inhibition, and xenograft validation","pmids":["33069770"],"confidence":"High","gaps":["Signaling steps linking GPER1 activation to SPOP upregulation not mapped","Whether SPOP induction is transcriptional or post-translational unclear"]},{"year":2021,"claim":"Genetic knockout established GPER1 as a necessary suppressor of type I interferon signaling that protects fetal development during maternal inflammation.","evidence":"GPER1 knockout mice, maternal inflammation models, and tissue-specific IFN signaling comparison","pmids":["33446553"],"confidence":"High","gaps":["Molecular link between GPER1 and IFN pathway components not defined","Cell type mediating tissue-selective suppression unidentified"]},{"year":2014,"claim":"Extended GPER1 outputs to steroidogenesis and matrix biology, showing PKA-driven aldosterone synthase induction and integrin α5β1–Shc–dependent fibronectin assembly.","evidence":"Agonist/antagonist plus gene silencing for aldosterone (HAC15 cells) and Shc Y317F mutagenesis with adhesion/haptotaxis assays","pmids":["25167221","25096985"],"confidence":"Medium","gaps":["Single-lab findings for each role","Interplay with ERβ in steroidogenic regulation only partially mapped"]},{"year":2013,"claim":"Defined GPER1 control of vascular tone through EGFR/Src/Akt-dependent vasorelaxation and L-type Ca2+ channel inhibition in smooth muscle.","evidence":"Ex vivo aortic/renal preparations and A7r5 Ca2+ imaging with selective kinase and channel inhibitors plus GPER1 antagonists","pmids":["24028616","24080531","23376418"],"confidence":"Medium","gaps":["Pharmacology-only dissection without genetic confirmation in vessels","Reconciliation of vasoconstrictor versus vasodilator effects across beds incomplete"]},{"year":2020,"claim":"Implicated GPER1 in inflammatory suppression via physical partnership with ERα36 and direct interaction with NF-κB p65 to inhibit TLR4-driven cytokine production.","evidence":"Co-IP of GPER1 with ERα36 and p65, siRNA knockdown, and NF-κB reporter/cytokine assays in breast cancer cells and monocytes","pmids":["34299224","26394816"],"confidence":"Medium","gaps":["Reciprocal/structural validation of the GPER1–p65 interaction lacking","Whether GPER1 acts at the membrane or nucleus in this complex unclear"]},{"year":2019,"claim":"Identified autocrine motility factor as a direct GPER1-binding partner that co-translocates and activates PI3K/AKT to promote cancer cell growth.","evidence":"Yeast two-hybrid, Co-IP, immunofluorescence, iTRAQ proteomics, and xenograft model in endometrial cancer cells","pmids":["30836961"],"confidence":"Medium","gaps":["Binding interface and stoichiometry undefined","Physiological relevance outside cancer context untested"]},{"year":null,"claim":"How cell-type-specific localization and ligand identity dictate the choice among Gs, Gi/o, and Gq outputs, and the structural basis of GPER1 ligand recognition, remain unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model of ligand-bound GPER1 in the corpus","Determinants of plasma-membrane vs. endomembrane retention unknown","In vivo dominance of each G-protein pathway not established"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,2,18]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[27,28]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[1,2]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[2]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,1,2]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[14,27,28]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[3,6]},{"term_id":"R-HSA-112316","term_label":"Neuronal System","supporting_discovery_ids":[4,18]}],"complexes":[],"partners":["AKAP5","SAP97","ERA36","RELA","AMF","EGFR"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q99527","full_name":"G-protein coupled estrogen receptor 1","aliases":["Chemoattractant receptor-like 2","Flow-induced endothelial G-protein coupled receptor 1","FEG-1","G protein-coupled estrogen receptor 1","G-protein coupled receptor 30","GPCR-Br","IL8-related receptor DRY12","Lymphocyte-derived G-protein coupled receptor","LYGPR","Membrane estrogen receptor","mER"],"length_aa":375,"mass_kda":42.2,"function":"G-protein coupled estrogen receptor that binds to 17-beta-estradiol (E2) with high affinity, leading to rapid and transient activation of numerous intracellular signaling pathways. Stimulates cAMP production, calcium mobilization and tyrosine kinase Src inducing the release of heparin-bound epidermal growth factor (HB-EGF) and subsequent transactivation of the epidermal growth factor receptor (EGFR), activating downstream signaling pathways such as PI3K/Akt and ERK/MAPK. Mediates pleiotropic functions among others in the cardiovascular, endocrine, reproductive, immune and central nervous systems. Has a role in cardioprotection by reducing cardiac hypertrophy and perivascular fibrosis in a RAMP3-dependent manner. Regulates arterial blood pressure by stimulating vasodilation and reducing vascular smooth muscle and microvascular endothelial cell proliferation. Plays a role in blood glucose homeostasis contributing to the insulin secretion response by pancreatic beta cells. Triggers mitochondrial apoptosis during pachytene spermatocyte differentiation. Stimulates uterine epithelial cell proliferation. Enhances uterine contractility in response to oxytocin. Contributes to thymic atrophy by inducing apoptosis. Attenuates TNF-mediated endothelial expression of leukocyte adhesion molecules. Promotes neuritogenesis in developing hippocampal neurons. Plays a role in acute neuroprotection against NMDA-induced excitotoxic neuronal death. Increases firing activity and intracellular calcium oscillations in luteinizing hormone-releasing hormone (LHRH) neurons. Inhibits early osteoblast proliferation at growth plate during skeletal development. Inhibits mature adipocyte differentiation and lipid accumulation. Involved in the recruitment of beta-arrestin 2 ARRB2 at the plasma membrane in epithelial cells. Also functions as a receptor for aldosterone mediating rapid regulation of vascular contractibility through the PI3K/ERK signaling pathway. Involved in cancer progression regulation. Stimulates cancer-associated fibroblast (CAF) proliferation by a rapid genomic response through the EGFR/ERK transduction pathway. Associated with EGFR, may act as a transcription factor activating growth regulatory genes (c-fos, cyclin D1). Promotes integrin alpha-5/beta-1 and fibronectin (FN) matrix assembly in breast cancer cells","subcellular_location":"Nucleus; Cytoplasm; Cytoplasm, perinuclear region; Cytoplasm, cytoskeleton; Cell membrane; Basolateral cell membrane; Cytoplasmic vesicle membrane; Early endosome; Recycling endosome; Golgi apparatus membrane; Golgi apparatus, trans-Golgi network; Endoplasmic reticulum membrane; Cell projection, dendrite; Cell projection, dendritic spine membrane; Cell projection, axon; Postsynaptic density; Mitochondrion membrane","url":"https://www.uniprot.org/uniprotkb/Q99527/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/GPER1","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/GPER1","total_profiled":1310},"omim":[{"mim_id":"620560","title":"CEBPA DIVERGENT TRANSCRIPT; CEBPA-DT","url":"https://www.omim.org/entry/620560"},{"mim_id":"601805","title":"G PROTEIN-COUPLED ESTROGEN RECEPTOR 1; GPER1","url":"https://www.omim.org/entry/601805"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoli","reliability":"Supported"},{"location":"Nucleoplasm","reliability":"Additional"},{"location":"Vesicles","reliability":"Additional"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"stomach 1","ntpm":40.9}],"url":"https://www.proteinatlas.org/search/GPER1"},"hgnc":{"alias_symbol":["FEG-1","GPCR-Br","LERGU","LERGU2","DRY12","LyGPR","CEPR"],"prev_symbol":["CMKRL2","GPR30","GPER"]},"alphafold":{"accession":"Q99527","domains":[{"cath_id":"1.20.1070.10","chopping":"54-336","consensus_level":"high","plddt":86.6645,"start":54,"end":336}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q99527","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q99527-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q99527-F1-predicted_aligned_error_v6.png","plddt_mean":79.12},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=GPER1","jax_strain_url":"https://www.jax.org/strain/search?query=GPER1"},"sequence":{"accession":"Q99527","fasta_url":"https://rest.uniprot.org/uniprotkb/Q99527.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q99527/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q99527"}},"corpus_meta":[{"pmid":"22495674","id":"PMC_22495674","title":"Minireview: G protein-coupled estrogen receptor-1, GPER-1: its mechanism of action and role in female reproductive cancer, renal and vascular physiology.","date":"2012","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/22495674","citation_count":295,"is_preprint":false},{"pmid":"19734054","id":"PMC_19734054","title":"GPR30/GPER1: searching for a role in estrogen physiology.","date":"2009","source":"Trends in endocrinology and metabolism: TEM","url":"https://pubmed.ncbi.nlm.nih.gov/19734054","citation_count":186,"is_preprint":false},{"pmid":"26394816","id":"PMC_26394816","title":"Estrogen anti-inflammatory activity on human monocytes is mediated through cross-talk between estrogen receptor ERα36 and GPR30/GPER1.","date":"2015","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/26394816","citation_count":150,"is_preprint":false},{"pmid":"28465157","id":"PMC_28465157","title":"GPER1/GPR30 in the brain: Crosstalk with classical estrogen receptors and implications for behavior.","date":"2017","source":"The Journal of steroid biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/28465157","citation_count":89,"is_preprint":false},{"pmid":"23849542","id":"PMC_23849542","title":"GPER-1 acts as a tumor suppressor in ovarian cancer.","date":"2013","source":"Journal of ovarian research","url":"https://pubmed.ncbi.nlm.nih.gov/23849542","citation_count":86,"is_preprint":false},{"pmid":"25980457","id":"PMC_25980457","title":"Contribution of estrogen receptor subtypes, ERα, ERβ, and GPER1 in rapid estradiol-mediated enhancement of hippocampal synaptic transmission in mice.","date":"2015","source":"Hippocampus","url":"https://pubmed.ncbi.nlm.nih.gov/25980457","citation_count":81,"is_preprint":false},{"pmid":"21250980","id":"PMC_21250980","title":"G protein-coupled oestrogen receptor 1 (GPER1)/GPR30: a new player in cardiovascular and metabolic oestrogenic signalling.","date":"2011","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/21250980","citation_count":76,"is_preprint":false},{"pmid":"27392633","id":"PMC_27392633","title":"Emerging roles for the novel estrogen-sensing receptor GPER1 in the CNS.","date":"2016","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/27392633","citation_count":68,"is_preprint":false},{"pmid":"21273787","id":"PMC_21273787","title":"The GPER1 agonist G-1 attenuates endothelial cell proliferation by inhibiting DNA synthesis and accumulating cells in the S and G2 phases of the cell cycle.","date":"2011","source":"Journal of vascular research","url":"https://pubmed.ncbi.nlm.nih.gov/21273787","citation_count":60,"is_preprint":false},{"pmid":"26391661","id":"PMC_26391661","title":"A novel form of synaptic plasticity in field CA3 of hippocampus requires GPER1 activation and BDNF release.","date":"2015","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/26391661","citation_count":60,"is_preprint":false},{"pmid":"25167221","id":"PMC_25167221","title":"GPER-1 and estrogen receptor-β ligands modulate aldosterone synthesis.","date":"2014","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/25167221","citation_count":57,"is_preprint":false},{"pmid":"28348059","id":"PMC_28348059","title":"The Glycolytic Enzyme PFKFB3 Is Involved in Estrogen-Mediated Angiogenesis via GPER1.","date":"2017","source":"The Journal of pharmacology and experimental therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/28348059","citation_count":56,"is_preprint":false},{"pmid":"32401166","id":"PMC_32401166","title":"Stabilization of MORC2 by estrogen and antiestrogens through GPER1- PRKACA-CMA pathway contributes to estrogen-induced proliferation and endocrine resistance of breast cancer cells.","date":"2019","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/32401166","citation_count":55,"is_preprint":false},{"pmid":"25236887","id":"PMC_25236887","title":"GPER1 (GPR30) knockout mice display reduced anxiety and altered stress response in a sex and paradigm dependent manner.","date":"2014","source":"Hormones and behavior","url":"https://pubmed.ncbi.nlm.nih.gov/25236887","citation_count":55,"is_preprint":false},{"pmid":"24736568","id":"PMC_24736568","title":"Activation of GPER-1 estradiol receptor downregulates production of testosterone in isolated rat Leydig cells and adult human testis.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24736568","citation_count":55,"is_preprint":false},{"pmid":"27311857","id":"PMC_27311857","title":"Activation of G protein-coupled estrogen receptor 1 (GPER-1) ameliorates blood-brain barrier permeability after global cerebral ischemia in ovariectomized rats.","date":"2016","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/27311857","citation_count":54,"is_preprint":false},{"pmid":"33446553","id":"PMC_33446553","title":"GPER1 is required to protect fetal health from maternal inflammation.","date":"2021","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/33446553","citation_count":53,"is_preprint":false},{"pmid":"30354811","id":"PMC_30354811","title":"Attenuation of Microbiotal Dysbiosis and Hypertension in a CRISPR/Cas9 Gene Ablation Rat Model of GPER1.","date":"2018","source":"Hypertension (Dallas, Tex. : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/30354811","citation_count":51,"is_preprint":false},{"pmid":"22749492","id":"PMC_22749492","title":"Implication of GPER1 in neuroprotection in a mouse model of Parkinson's disease.","date":"2012","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/22749492","citation_count":49,"is_preprint":false},{"pmid":"26345541","id":"PMC_26345541","title":"Prunetin signals via G-protein-coupled receptor, GPR30(GPER1): Stimulation of adenylyl cyclase and cAMP-mediated activation of MAPK signaling induces Runx2 expression in osteoblasts to promote bone regeneration.","date":"2015","source":"The Journal of nutritional biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26345541","citation_count":48,"is_preprint":false},{"pmid":"23483801","id":"PMC_23483801","title":"GPER1/GPR30 activation improves neuronal survival following global cerebral ischemia induced by cardiac arrest in mice.","date":"2012","source":"Translational stroke research","url":"https://pubmed.ncbi.nlm.nih.gov/23483801","citation_count":48,"is_preprint":false},{"pmid":"28450397","id":"PMC_28450397","title":"G protein-coupled estrogen receptor 1 (GPER1)/GPR30 increases ERK1/2 activity through PDZ motif-dependent and -independent mechanisms.","date":"2017","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28450397","citation_count":46,"is_preprint":false},{"pmid":"26051538","id":"PMC_26051538","title":"GPER1-mediated immunomodulation and neuroprotection in the myenteric plexus of a mouse model of Parkinson's disease.","date":"2015","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/26051538","citation_count":46,"is_preprint":false},{"pmid":"23688258","id":"PMC_23688258","title":"GPER-1 expression decreases during breast cancer tumorigenesis.","date":"2013","source":"Cancer investigation","url":"https://pubmed.ncbi.nlm.nih.gov/23688258","citation_count":44,"is_preprint":false},{"pmid":"25451689","id":"PMC_25451689","title":"Ceramide synthases CerS4 and CerS5 are upregulated by 17β-estradiol and GPER1 via AP-1 in human breast cancer cells.","date":"2014","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/25451689","citation_count":41,"is_preprint":false},{"pmid":"30478785","id":"PMC_30478785","title":"G-protein-coupled estrogen receptor GPER-1 expression in hormone receptor-positive breast cancer is associated with poor benefit of tamoxifen.","date":"2018","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/30478785","citation_count":40,"is_preprint":false},{"pmid":"33425895","id":"PMC_33425895","title":"GPER1 Silencing Suppresses the Proliferation, Migration, and Invasion of Gastric Cancer Cells by Inhibiting PI3K/AKT-Mediated EMT.","date":"2020","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/33425895","citation_count":39,"is_preprint":false},{"pmid":"25012984","id":"PMC_25012984","title":"GPER1 is regulated by insulin in cancer cells and cancer-associated fibroblasts.","date":"2014","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/25012984","citation_count":38,"is_preprint":false},{"pmid":"33117280","id":"PMC_33117280","title":"Continuous Exposure of Breast Cancer Cells to Tamoxifen Upregulates GPER-1 and Increases Cell Proliferation.","date":"2020","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/33117280","citation_count":37,"is_preprint":false},{"pmid":"25031742","id":"PMC_25031742","title":"High expression of GPER1, EGFR and CXCR1 is associated with lymph node metastasis in papillary thyroid carcinoma.","date":"2014","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/25031742","citation_count":35,"is_preprint":false},{"pmid":"23907016","id":"PMC_23907016","title":"17β-estradiol promotes the invasion and migration of nuclear estrogen receptor-negative breast cancer cells through cross-talk between GPER1 and CXCR1.","date":"2013","source":"The Journal of steroid biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/23907016","citation_count":35,"is_preprint":false},{"pmid":"21196169","id":"PMC_21196169","title":"Role of estrogen receptors alpha, beta and GPER1/GPR30 in pancreatic beta-cells.","date":"2011","source":"Frontiers in bioscience (Landmark edition)","url":"https://pubmed.ncbi.nlm.nih.gov/21196169","citation_count":33,"is_preprint":false},{"pmid":"24188886","id":"PMC_24188886","title":"GPCR-mediated rapid, non-genomic actions of steroids: comparisons between DmDopEcR and GPER1 (GPR30).","date":"2013","source":"General and comparative endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/24188886","citation_count":32,"is_preprint":false},{"pmid":"26998610","id":"PMC_26998610","title":"Characterisation of Signalling by the Endogenous GPER1 (GPR30) Receptor in an Embryonic Mouse Hippocampal Cell Line (mHippoE-18).","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26998610","citation_count":31,"is_preprint":false},{"pmid":"27113328","id":"PMC_27113328","title":"GPER1 mediates estrogen-induced neuroprotection against oxygen-glucose deprivation in the primary hippocampal neurons.","date":"2016","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/27113328","citation_count":30,"is_preprint":false},{"pmid":"30195206","id":"PMC_30195206","title":"Low-concentration BPF induced cell biological responses by the ERα and GPER1-mediated signaling pathways in MCF-7 breast cancer cells.","date":"2018","source":"Ecotoxicology and environmental safety","url":"https://pubmed.ncbi.nlm.nih.gov/30195206","citation_count":30,"is_preprint":false},{"pmid":"31635400","id":"PMC_31635400","title":"A Novel Mechanism of S-equol Action in Neurons and Astrocytes: The Possible Involvement of GPR30/GPER1.","date":"2019","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31635400","citation_count":30,"is_preprint":false},{"pmid":"29964007","id":"PMC_29964007","title":"Is the membrane estrogen receptor, GPER1, a promiscuous receptor that modulates nuclear estrogen receptor-mediated functions in the brain?","date":"2018","source":"Hormones and behavior","url":"https://pubmed.ncbi.nlm.nih.gov/29964007","citation_count":29,"is_preprint":false},{"pmid":"28263910","id":"PMC_28263910","title":"Depressive-like effect of prenatal exposure to DDT involves global DNA hypomethylation and impairment of GPER1/ESR1 protein levels but not ESR2 and AHR/ARNT signaling.","date":"2017","source":"The Journal of steroid biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/28263910","citation_count":28,"is_preprint":false},{"pmid":"30836961","id":"PMC_30836961","title":"Autocrine motility factor promotes endometrial cancer progression by targeting GPER-1.","date":"2019","source":"Cell communication and signaling : CCS","url":"https://pubmed.ncbi.nlm.nih.gov/30836961","citation_count":26,"is_preprint":false},{"pmid":"23376418","id":"PMC_23376418","title":"Vasoconstriction induced by G1, a G-protein-coupled oestrogen receptor1 (GPER-1) agonist, in the isolated perfused rat kidney.","date":"2013","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/23376418","citation_count":26,"is_preprint":false},{"pmid":"33281743","id":"PMC_33281743","title":"G Protein-Coupled Estrogen Receptor, GPER1, Offers a Novel Target for the Treatment of Digestive Diseases.","date":"2020","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/33281743","citation_count":25,"is_preprint":false},{"pmid":"25823895","id":"PMC_25823895","title":"17β-estradiol inhibits spreading of metastatic cells from granulosa cell tumors through a non-genomic mechanism involving GPER1.","date":"2015","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/25823895","citation_count":25,"is_preprint":false},{"pmid":"30267584","id":"PMC_30267584","title":"Shenmai injection improves the postoperative immune function of papillary thyroid carcinoma patients by inhibiting differentiation into Treg cells via miR-103/GPER1 axis.","date":"2018","source":"Drug development research","url":"https://pubmed.ncbi.nlm.nih.gov/30267584","citation_count":25,"is_preprint":false},{"pmid":"35520492","id":"PMC_35520492","title":"Sequential ligand- and structure-based virtual screening approach for the identification of potential G protein-coupled estrogen receptor-1 (GPER-1) modulators.","date":"2019","source":"RSC advances","url":"https://pubmed.ncbi.nlm.nih.gov/35520492","citation_count":25,"is_preprint":false},{"pmid":"30092317","id":"PMC_30092317","title":"Role of estrogens in fish immunity with special emphasis on GPER1.","date":"2018","source":"Developmental and comparative immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30092317","citation_count":24,"is_preprint":false},{"pmid":"26772481","id":"PMC_26772481","title":"Understanding the molecular basis of agonist/antagonist mechanism of GPER1/GPR30 through structural and energetic analyses.","date":"2016","source":"The Journal of steroid biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/26772481","citation_count":24,"is_preprint":false},{"pmid":"31586450","id":"PMC_31586450","title":"The neuroprotective effects of novel estrogen receptor GPER1 in mouse retinal ganglion cell degeneration.","date":"2019","source":"Experimental eye research","url":"https://pubmed.ncbi.nlm.nih.gov/31586450","citation_count":23,"is_preprint":false},{"pmid":"27512921","id":"PMC_27512921","title":"Serum levels of G protein-coupled estrogen receptor 1 (GPER1) in drug-naive patients with generalized anxiety disorder.","date":"2016","source":"Psychiatry research","url":"https://pubmed.ncbi.nlm.nih.gov/27512921","citation_count":23,"is_preprint":false},{"pmid":"24080531","id":"PMC_24080531","title":"The G protein-coupled estrogen receptor 1 (GPER1/GPR30) agonist G-1 regulates vascular smooth muscle cell Ca²⁺ handling.","date":"2013","source":"Journal of vascular research","url":"https://pubmed.ncbi.nlm.nih.gov/24080531","citation_count":23,"is_preprint":false},{"pmid":"24718680","id":"PMC_24718680","title":"Icariin and icaritin stimulate the proliferation of SKBr3 cells through the GPER1-mediated modulation of the EGFR-MAPK signaling pathway.","date":"2014","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24718680","citation_count":23,"is_preprint":false},{"pmid":"30405852","id":"PMC_30405852","title":"Oestrogen Inhibits VEGF Expression And Angiogenesis In Triple-Negative Breast Cancer By Activating GPER-1.","date":"2018","source":"Journal of Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/30405852","citation_count":22,"is_preprint":false},{"pmid":"24028616","id":"PMC_24028616","title":"GPER-1 agonist G1 induces vasorelaxation through activation of epidermal growth factor receptor-dependent signalling pathway.","date":"2013","source":"The Journal of pharmacy and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/24028616","citation_count":22,"is_preprint":false},{"pmid":"26981789","id":"PMC_26981789","title":"The protective role of G protein-coupled estrogen receptor 1 (GPER-1) on methotrexate-induced nephrotoxicity in human renal epithelium cells.","date":"2016","source":"Renal failure","url":"https://pubmed.ncbi.nlm.nih.gov/26981789","citation_count":22,"is_preprint":false},{"pmid":"26722308","id":"PMC_26722308","title":"Oxidative/antioxidative enzyme-mediated antiproliferative and proapoptotic effects of the GPER1 agonist G-1 on lung cancer cells.","date":"2015","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/26722308","citation_count":21,"is_preprint":false},{"pmid":"25096985","id":"PMC_25096985","title":"The G protein-coupled estrogen receptor-1, GPER-1, promotes fibrillogenesis via a Shc-dependent pathway resulting in anchorage-independent growth.","date":"2014","source":"Hormones & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/25096985","citation_count":21,"is_preprint":false},{"pmid":"32813115","id":"PMC_32813115","title":"G protein-coupled estrogen receptor 1 (GPER-1) and agonist G-1 inhibit growth of ovarian cancer cells by activation of anti-tumoral transcriptome responses: impact of GPER-1 mRNA on survival.","date":"2020","source":"Journal of cancer research and clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/32813115","citation_count":21,"is_preprint":false},{"pmid":"28286086","id":"PMC_28286086","title":"Hyper-methylation of the upstream CpG island shore is a likely mechanism of GPER1 silencing in breast cancer cells.","date":"2017","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/28286086","citation_count":21,"is_preprint":false},{"pmid":"34299224","id":"PMC_34299224","title":"ERα36-GPER1 Collaboration Inhibits TLR4/NFκB-Induced Pro-Inflammatory Activity in Breast Cancer Cells.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34299224","citation_count":20,"is_preprint":false},{"pmid":"34714484","id":"PMC_34714484","title":"Saikosaponin-d alleviates hepatic fibrosis through regulating GPER1/autophagy signaling.","date":"2021","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/34714484","citation_count":20,"is_preprint":false},{"pmid":"34248622","id":"PMC_34248622","title":"Bazi Bushen Capsule Alleviates Post-Menopausal Atherosclerosis via GPER1-Dependent Anti-Inflammatory and Anti-Apoptotic Effects.","date":"2021","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/34248622","citation_count":20,"is_preprint":false},{"pmid":"26093261","id":"PMC_26093261","title":"Activation of G protein-coupled estrogen receptor 1 (GPER-1) decreases fluid intake in female rats.","date":"2015","source":"Hormones and behavior","url":"https://pubmed.ncbi.nlm.nih.gov/26093261","citation_count":20,"is_preprint":false},{"pmid":"31900584","id":"PMC_31900584","title":"GPER-1 expression is associated with a decreased response rate to primary tamoxifen therapy of breast cancer patients.","date":"2020","source":"Archives of gynecology and obstetrics","url":"https://pubmed.ncbi.nlm.nih.gov/31900584","citation_count":19,"is_preprint":false},{"pmid":"31082617","id":"PMC_31082617","title":"GPER1 influences cellular homeostasis and cytostatic drug resistance via influencing long chain ceramide synthesis in breast cancer cells.","date":"2019","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/31082617","citation_count":18,"is_preprint":false},{"pmid":"33193108","id":"PMC_33193108","title":"Does GPER1 Play a Role in Sexual Dimorphism?","date":"2020","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/33193108","citation_count":17,"is_preprint":false},{"pmid":"31040364","id":"PMC_31040364","title":"Targeting GPER1 to suppress autophagy as a male-specific therapeutic strategy for iron-induced striatal injury.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31040364","citation_count":17,"is_preprint":false},{"pmid":"33069770","id":"PMC_33069770","title":"The GPER1/SPOP axis mediates ubiquitination-dependent degradation of ERα to inhibit the growth of breast cancer induced by oestrogen.","date":"2020","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/33069770","citation_count":17,"is_preprint":false},{"pmid":"32302699","id":"PMC_32302699","title":"The novel estrogen receptor GPER1 decreases epilepsy severity and susceptivity in the hippocampus after status epilepticus.","date":"2020","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/32302699","citation_count":16,"is_preprint":false},{"pmid":"32077170","id":"PMC_32077170","title":"The G protein-coupled oestrogen receptor, GPER1, mediates direct anti-inflammatory effects of oestrogens in human cholinergic neurones from the nucleus basalis of Meynert.","date":"2020","source":"Journal of neuroendocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/32077170","citation_count":16,"is_preprint":false},{"pmid":"31698960","id":"PMC_31698960","title":"Environmental polycyclic aromatic hydrocarbons mixture, in human blood levels, decreased oestradiol secretion by granulosa cells via ESR1 and GPER1 but not ESR2 receptor.","date":"2019","source":"Human & experimental toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/31698960","citation_count":16,"is_preprint":false},{"pmid":"29807036","id":"PMC_29807036","title":"Selective activation of estrogen receptors, ERα and GPER-1, rapidly decreases food intake in female rats.","date":"2018","source":"Hormones and behavior","url":"https://pubmed.ncbi.nlm.nih.gov/29807036","citation_count":16,"is_preprint":false},{"pmid":"25402859","id":"PMC_25402859","title":"GPER1 stimulation alters posttranslational modification of RGSz1 and induces desensitization of 5-HT1A receptor signaling in the rat hypothalamus.","date":"2014","source":"Neuroendocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/25402859","citation_count":15,"is_preprint":false},{"pmid":"26690777","id":"PMC_26690777","title":"GPER1-mediated IGFBP-1 induction modulates IGF-1-dependent signaling in tamoxifen-treated breast cancer cells.","date":"2015","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/26690777","citation_count":14,"is_preprint":false},{"pmid":"36288854","id":"PMC_36288854","title":"Suppression of G Protein-coupled Estrogen Receptor 1 (GPER1) Enhances the Anti-invasive Efficacy of Selective ERβ Agonists.","date":"2022","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/36288854","citation_count":14,"is_preprint":false},{"pmid":"35803362","id":"PMC_35803362","title":"Bisphenol F blocks Leydig cell maturation and steroidogenesis in pubertal male rats through suppressing androgen receptor signaling and activating G-protein coupled estrogen receptor 1 (GPER1) signaling.","date":"2022","source":"Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association","url":"https://pubmed.ncbi.nlm.nih.gov/35803362","citation_count":14,"is_preprint":false},{"pmid":"33193095","id":"PMC_33193095","title":"Chronic GPER1 Activation Protects Against Oxidative Stress-Induced Cardiomyoblast Death via Preservation of Mitochondrial Integrity and Deactivation of Mammalian Sterile-20-Like Kinase/Yes-Associated Protein Pathway.","date":"2020","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/33193095","citation_count":14,"is_preprint":false},{"pmid":"38086848","id":"PMC_38086848","title":"Activation of GPER1 in macrophages ameliorates UUO-induced renal fibrosis.","date":"2023","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/38086848","citation_count":13,"is_preprint":false},{"pmid":"37093686","id":"PMC_37093686","title":"Knockdown of G Protein-coupled Estrogen Receptor 1 (GPER1) Enhances Tumor-supportive Properties in Cervical Carcinoma Cells.","date":"2023","source":"Cancer genomics & proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/37093686","citation_count":13,"is_preprint":false},{"pmid":"38217667","id":"PMC_38217667","title":"Activation of GPER-1 Attenuates Traumatic Brain Injury-Induced Neurological Impairments in Mice.","date":"2024","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/38217667","citation_count":13,"is_preprint":false},{"pmid":"37746893","id":"PMC_37746893","title":"Orchestrated feedback regulation between melatonin and sex hormones involving GPER1-PKA-CREB signaling in the placenta.","date":"2023","source":"Journal of pineal research","url":"https://pubmed.ncbi.nlm.nih.gov/37746893","citation_count":13,"is_preprint":false},{"pmid":"33014211","id":"PMC_33014211","title":"MiR-155-Mediated Deregulation of GPER1 Plays an Important Role in the Gender Differences Related to Inflammatory Bowel Disease.","date":"2020","source":"The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale","url":"https://pubmed.ncbi.nlm.nih.gov/33014211","citation_count":13,"is_preprint":false},{"pmid":"35537249","id":"PMC_35537249","title":"Changes in expression of signal transduction-related genes, and formation of aggregates of GPER1 and OXTR receptors in mucopolysaccharidosis cells.","date":"2022","source":"European journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/35537249","citation_count":12,"is_preprint":false},{"pmid":"23641788","id":"PMC_23641788","title":"G protein-coupled estrogen receptor1 (GPER1) may mediate Rho-kinase (ROCK-2) up-regulation in coronary endothelial cells.","date":"2013","source":"Endocrine regulations","url":"https://pubmed.ncbi.nlm.nih.gov/23641788","citation_count":11,"is_preprint":false},{"pmid":"28688795","id":"PMC_28688795","title":"GPER1 in sand rat epididymis: Effects of seasonal variations, castration and efferent ducts ligation.","date":"2017","source":"Animal reproduction science","url":"https://pubmed.ncbi.nlm.nih.gov/28688795","citation_count":11,"is_preprint":false},{"pmid":"27546037","id":"PMC_27546037","title":"Homology Modeling, Validation and Dynamics of the G Protein-coupled Estrogen Receptor 1 (GPER-1).","date":"2016","source":"Molecular informatics","url":"https://pubmed.ncbi.nlm.nih.gov/27546037","citation_count":11,"is_preprint":false},{"pmid":"28374135","id":"PMC_28374135","title":"Oxabicycloheptene Sulfonate Protects Against β-Amyloid-induced Toxicity by Activation of PI3K/Akt and ERK Signaling Pathways Via GPER1 in C6 Cells.","date":"2017","source":"Neurochemical research","url":"https://pubmed.ncbi.nlm.nih.gov/28374135","citation_count":11,"is_preprint":false},{"pmid":"29618927","id":"PMC_29618927","title":"Serum levels of GPER-1 in euthymic bipolar patients.","date":"2018","source":"Neuropsychiatric disease and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/29618927","citation_count":11,"is_preprint":false},{"pmid":"38880044","id":"PMC_38880044","title":"Selenium restored mitophagic flux to alleviate cadmium-induced hepatotoxicity by inhibiting excessive GPER1-mediated mitophagy activation.","date":"2024","source":"Journal of hazardous materials","url":"https://pubmed.ncbi.nlm.nih.gov/38880044","citation_count":10,"is_preprint":false},{"pmid":"37399525","id":"PMC_37399525","title":"GPER1 deficiency causes sex-specific dysregulation of hippocampal plasticity and cognitive function.","date":"2023","source":"The Journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/37399525","citation_count":10,"is_preprint":false},{"pmid":"35569583","id":"PMC_35569583","title":"Bisphenol S induces Agrp expression through GPER1 activation and alters transcription factor expression in immortalized hypothalamic neurons: A mechanism distinct from BPA-induced upregulation.","date":"2022","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/35569583","citation_count":10,"is_preprint":false},{"pmid":"38992889","id":"PMC_38992889","title":"Activation of GPER1 by G1 prevents PTSD-like behaviors in mice: Illustrating the mechanisms from BDNF/TrkB to mitochondria and synaptic connection.","date":"2024","source":"CNS neuroscience & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/38992889","citation_count":10,"is_preprint":false},{"pmid":"29269179","id":"PMC_29269179","title":"Lordosis facilitated by GPER-1 receptor activation involves GnRH-1, progestin and estrogen receptors in estrogen-primed rats.","date":"2018","source":"Hormones and behavior","url":"https://pubmed.ncbi.nlm.nih.gov/29269179","citation_count":10,"is_preprint":false},{"pmid":"29745344","id":"PMC_29745344","title":"Selection of a GPER1 Ligand via Ligand-based Virtual Screening Coupled to Molecular Dynamics Simulations and Its Anti-proliferative Effects on Breast Cancer Cells.","date":"2018","source":"Anti-cancer agents in medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29745344","citation_count":10,"is_preprint":false},{"pmid":"31790688","id":"PMC_31790688","title":"GPER1 in the thyroid: A systematic review.","date":"2019","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31790688","citation_count":9,"is_preprint":false},{"pmid":"33374170","id":"PMC_33374170","title":"GPER1 and microRNA: Two Players in Breast Cancer Progression.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33374170","citation_count":9,"is_preprint":false},{"pmid":"36096380","id":"PMC_36096380","title":"Overexpression of estrogen receptor GPER1 and G1 treatment reduces SARS-CoV-2 infection in BEAS-2B bronchial cells.","date":"2022","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/36096380","citation_count":9,"is_preprint":false},{"pmid":"37759449","id":"PMC_37759449","title":"GPER1 Activation Exerts Anti-Tumor Activity in Multiple Myeloma.","date":"2023","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/37759449","citation_count":9,"is_preprint":false},{"pmid":"36400433","id":"PMC_36400433","title":"Multiplex G Protein-Coupled Receptor Screen Reveals Reliably Acting Agonists and a Gq-Phospholipase C Coupling Mode of GPR30/GPER1.","date":"2022","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/36400433","citation_count":9,"is_preprint":false},{"pmid":"34239558","id":"PMC_34239558","title":"G Protein-Coupled Estrogen Receptor 1 (GPER1) Mediates Aldosterone-Induced Endothelial Inflammation in a Mineralocorticoid Receptor-Independent Manner.","date":"2021","source":"International journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/34239558","citation_count":9,"is_preprint":false},{"pmid":"31434056","id":"PMC_31434056","title":"Effects of the selective GPER1 agonist G1 on bone growth.","date":"2019","source":"Endocrine connections","url":"https://pubmed.ncbi.nlm.nih.gov/31434056","citation_count":9,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":54821,"output_tokens":9503,"usd":0.153504,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":19722,"output_tokens":4069,"usd":0.100168,"stage2_stop_reason":"end_turn"},"total_usd":0.253672,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2012,\n      \"finding\": \"GPER-1 (GPR30) is a Gs-coupled heptahelical transmembrane receptor that stimulates adenylyl cyclase and promotes Gβγ-subunit protein-dependent release of membrane-tethered heparan-bound epidermal growth factor (HB-EGF); selective agonists/antagonists discriminate it from nuclear ERα and ERβ.\",\n      \"method\": \"Pharmacological agonist/antagonist studies, receptor knockdown, cAMP assays\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — pharmacological dissection replicated across multiple labs, receptor knockdown controls, widely cited consensus mechanism\",\n      \"pmids\": [\"22495674\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"GPR30/GPER1 increases ERK1/2 activity via two distinct Gi/o-mediated mechanisms: (1) a PDZ motif-dependent constitutive mechanism requiring AKAP5, and (2) a PDZ-independent G-1-stimulated mechanism; the PDZ interaction with SAP97 and AKAP5 anchors the receptor at the plasma membrane and also mediates a constitutive decrease in cAMP independently of Gi/o.\",\n      \"method\": \"PDZ motif deletion mutants, AKAP5 knockdown, pertussis toxin (Gi/o inhibitor), PI3K inhibitor wortmannin, EGFR inhibitor AG1478, phosphatase inhibitors FK506 and okadaic acid; ERK1/2 activity assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — multiple orthogonal pharmacological and genetic approaches (mutagenesis of PDZ motif, specific knockdowns, kinase inhibitors) in one rigorous study\",\n      \"pmids\": [\"28450397\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"GPR30/GPER1 couples to the canonical Gq-phospholipase C pathway, activating protein kinase C and ERK; the receptor undergoes internalization upon continuous agonist exposure. Cell-line-dependent localization (plasma membrane in HEK293 and MCF-7; endomembrane retention in Cos-7 and HeLa) explains conflicting signaling reports. Classical agonists (17β-estradiol, 4-OHT, G-1) did not reproduce cAMP increases in this system.\",\n      \"method\": \"Multiplexed GPCR Ca2+ screen, stable/transient overexpression in HEK293 and multiple cell lines, Gq inhibitor YM-254890, PLC and PKC pathway analysis, receptor internalization assay, fluorescent fusion protein imaging\",\n      \"journal\": \"Molecular pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — rigorous unbiased GPCR screen with orthogonal pathway characterization (Ca2+, Gq inhibitor, PKC, ERK, internalization) in single study with multiple cell lines\",\n      \"pmids\": [\"36400433\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"GPER1 activates PRKACA (protein kinase A catalytic subunit alpha), which phosphorylates MORC2 at threonine 582; phosphorylated MORC2 reduces its interaction with HSPA8 and LAMP2A (chaperone-mediated autophagy components), protecting MORC2 from lysosomal degradation. A phosphorylation-lacking MORC2 T582A mutant cannot restore antiestrogen resistance.\",\n      \"method\": \"Co-immunoprecipitation, phosphorylation-site mutagenesis (T582A), CMA pathway inhibition, GPER1-dependent PRKACA activation assays, knockdown and rescue experiments in breast cancer cells\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — mutagenesis of phosphorylation site, co-IP, pathway dissection with multiple complementary approaches in single rigorous study\",\n      \"pmids\": [\"32401166\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"GPER1 activation triggers BDNF release in hippocampal field CA3, leading to transient stimulation of Arc protein translation and GluA1-containing AMPA receptor internalization; mGluR-dependent LTD at the mossy fiber pathway requires prior GPER1 stimulation and is associated with ubiquitin-proteasome-mediated degradation of GluA1.\",\n      \"method\": \"Selective GPER1 agonist G1, BDNF release assay, Arc translation assay, GluA1 internalization assay, proteasome inhibition, live hippocampal slice electrophysiology\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — multiple orthogonal biochemical and electrophysiological methods in single rigorous study establishing novel synaptic mechanism\",\n      \"pmids\": [\"26391661\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"GPER-1 stimulation with selective agonist G-1 increases aldosterone synthase expression and aldosterone production via protein kinase A signaling in adrenocortical HAC15 cells; silencing of ERβ unmasks this stimulatory GPER-1 effect, while silencing of GPER-1 blunts aldosterone synthase expression and blocks E2-stimulated aldosterone production under ERβ blockade.\",\n      \"method\": \"GPER-1 agonist G-1, GPER-1 antagonist G-15, selective PKA inhibitor, gene silencing (ERβ and GPER-1 siRNA), aldosterone synthase expression assays, aldosterone production measurement\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological agonism/antagonism combined with gene silencing and rescue, multiple complementary readouts in single study\",\n      \"pmids\": [\"25167221\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"GPER1 negatively regulates ERα protein levels by upregulating the Cullin3-based E3 ubiquitin ligase adaptor SPOP, which promotes ubiquitin-proteasome-dependent degradation of ERα; SPOP depletion abrogates GPER1-induced ERα ubiquitination and degradation. GPER1 activation inhibits E2-induced ERα+ breast cancer cell proliferation in vitro and tumor growth in vivo.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay, SPOP knockdown rescue experiments, proteasome inhibition, in vivo xenograft model\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — direct ubiquitination assay, Co-IP, genetic knockdown rescue, and in vivo validation in single rigorous study\",\n      \"pmids\": [\"33069770\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"GPER-1 promotes fibronectin (FN) matrix assembly and release of HB-EGF; GPER-1 stimulation forms integrin α5β1-Shc adaptor protein complexes at fibrillar adhesions. Shc mutant Y317F (lacking primary tyrosyl phosphorylation site) disrupts E2-induced focal adhesion and actin stress fiber formation and abolishes E2-enhanced haptotaxis and FN-dependent anchorage-independent growth.\",\n      \"method\": \"Stable Shc Y317F mutant expression, focal adhesion and actin stress fiber imaging, haptotaxis assays, hanging-drop anchorage-independent growth assay, immunoprecipitation of integrin α5β1-Shc complexes\",\n      \"journal\": \"Hormones & cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — phosphorylation-site mutagenesis with functional readouts, but single lab\",\n      \"pmids\": [\"25096985\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Estrogen-induced angiogenesis via GPER1 requires upregulation of the glycolytic enzyme PFKFB3 in HUVECs; GPER1 antagonist G-15 or GPER1 siRNA abolishes E2-induced PFKFB3 expression, and PFKFB3 inhibition blocks GPER1-mediated HUVEC migration.\",\n      \"method\": \"GPER1-selective agonist G-1, GPER1 antagonist G-15, GPER1 siRNA, PFKFB3 inhibitor, HUVEC migration and angiogenesis assays, PFKFB3 expression measurement\",\n      \"journal\": \"The Journal of pharmacology and experimental therapeutics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological and siRNA approaches with functional readouts, single lab\",\n      \"pmids\": [\"28348059\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"GPER-1-mediated vasoconstriction in isolated rat kidney involves ROCK, PKC, p38 MAPK, p42/44 MAPK, tyrosine kinase, EGF receptor kinase and voltage-operated Ca2+ channels but not JNK or PI3K; the effect is endothelium-independent and blocked by GPER-1 antagonist G15.\",\n      \"method\": \"Isolated perfused rat kidney, selective kinase inhibitors (Y-27632 for ROCK, PD98059 for ERK, SB203580 for p38, GF109203X for PKC, genistein for tyrosine kinase, AG-1478 for EGFR, nifedipine for Ca2+ channels), endothelium removal with saponin, Western blot for GPER-1 expression\",\n      \"journal\": \"European journal of pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple pathway inhibitors in intact organ preparation, single lab\",\n      \"pmids\": [\"23376418\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"GPER-1 agonist G1 induces endothelium-dependent vasorelaxation via Src-mediated transactivation of the EGF receptor, followed by Akt pathway activation; this is blocked by NOS inhibitor L-NAME, EGFR blockers AG1478 and DAPH, Src inhibitor, and Akt inhibitor VIII, but not by classical ER antagonists, PI3K inhibitors or ERK inhibitor.\",\n      \"method\": \"Rat aortic ring organ bath experiments, selective inhibitors of NOS, EGFR, Src, Akt, PI3K, ERK; GPER-1 antagonist HB-EGF\",\n      \"journal\": \"The Journal of pharmacy and pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological pathway dissection with multiple inhibitors in ex vivo tissue, single lab\",\n      \"pmids\": [\"24028616\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"GPER-1 agonist G1 reduces vascular smooth muscle cell Ca2+ spike activity by blocking voltage-sensitive L-type Ca2+ channels; the effect is blocked by GPER-1 antagonist G15, supporting a GPER-1-dependent mechanism for blood pressure regulation.\",\n      \"method\": \"Ca2+ imaging in A7r5 smooth muscle cells, L-type Ca2+ channel blocker nifedipine, GPER-1 antagonist G15, thromboxane A2 analogue stimulation, KCl-evoked Ca2+ measurement\",\n      \"journal\": \"Journal of vascular research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — live-cell Ca2+ imaging with pharmacological controls in defined cell line, single lab\",\n      \"pmids\": [\"24080531\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"GPER1 activation via G1 upregulates ROCK-2 expression in rat coronary vascular endothelial cells through GPER1 and EGFR transactivation; the effect requires Gi/o protein signaling (blocked by pertussis toxin), EGFR kinase (blocked by AG-1478), and de novo transcription (blocked by actinomycin-D), but is not replicated by ERα or ERβ selective agonists.\",\n      \"method\": \"Western blot for ROCK-2 and GPER1 in primary rat coronary vascular endothelial cells, GPER1 agonist G1, GPER1 antagonist G-15, pertussis toxin (Gi/o inhibitor), AG-1478 (EGFR blocker), actinomycin-D (transcription inhibitor), ERα/ERβ agonists\",\n      \"journal\": \"Endocrine regulations\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — pharmacological approach in primary cells without genetic confirmation, single lab, limited mechanistic resolution\",\n      \"pmids\": [\"23641788\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"GPER1 stimulation of 5-HT1A receptor desensitization in the rat hypothalamic paraventricular nucleus involves altered isoform expression and posttranslational modification of RGSz1; high-molecular-weight SUMOylated and glycosylated RGSz1 is increased by G-1 treatment and localizes to the detergent-resistant membrane microdomain, where it can reduce Gαz activity and uncouple 5-HT1AR signaling.\",\n      \"method\": \"Selective GPER1 agonist G-1, subcellular fractionation (detergent-resistant microdomains), Western blot for RGSz1 isoforms, SUMO and glycosylation analysis, oxytocin/ACTH hormonal response assays in vivo\",\n      \"journal\": \"Neuroendocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — subcellular fractionation and PTM characterization with in vivo hormonal readout, single lab\",\n      \"pmids\": [\"25402859\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"GPER1 activation during pregnancy suppresses interferon (IFN) signaling preferentially in reproductive and fetal tissues; GPER1 inactivation in mice caused fetal demise and halted fetal development only in the context of maternal inflammation, establishing GPER1 as a necessary regulator of type I IFN signaling that protects fetal health.\",\n      \"method\": \"GPER1 knockout mice, maternal inflammation models, IFN signaling assays in fetal vs. maternal tissues, tissue-specific comparison of IFN suppression\",\n      \"journal\": \"Science (New York, N.Y.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout with specific phenotypic readout (fetal demise in inflammatory context), published in high-impact journal with rigorous controls\",\n      \"pmids\": [\"33446553\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"GPER1 activation by 17β-estradiol inhibits constitutively active ERK1/2 in granulosa cell tumor cells and decreases migration and matrix invasion through non-genomic mechanisms; this anti-metastatic effect is mediated specifically by GPER1 signaling as demonstrated by pharmacological and RNA silencing approaches.\",\n      \"method\": \"Pharmacological GPER1 inhibitors, siRNA silencing of GPER1, ERK1/2 phosphorylation assays, migration and matrix invasion assays in KGN and COV434 cells\",\n      \"journal\": \"Carcinogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological and siRNA approaches with functional readouts, single lab\",\n      \"pmids\": [\"25823895\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"GPER-1 activation by E2 or selective agonist G-1 downregulates testosterone production in LH-stimulated isolated rat Leydig cells and in human testicular tissue by 20-30%; this is a GPER-1-specific effect as the testis lacks ERα.\",\n      \"method\": \"Isolated rat Leydig cells and human testis tissue, selective GPER-1 agonist G-1, ERα/β antagonist ICI 182,780, radioimmunoassay of testosterone, qRT-PCR and immunofluorescence for GPER-1 localization, MTS cell viability assay\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — primary cells and human tissue with pharmacological dissection, single lab\",\n      \"pmids\": [\"24736568\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Autocrine motility factor (AMF) physically binds to GPER-1, and the AMF-GPER-1 complex translocates from the plasma membrane to the cytoplasm; this interaction triggers PI3K/AKT signaling to promote endometrial cancer cell growth.\",\n      \"method\": \"Yeast two-hybrid assay, co-immunoprecipitation, immunofluorescence, iTRAQ proteomic analysis of downstream pathway, xenograft mouse model\",\n      \"journal\": \"Cell communication and signaling : CCS\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP confirmed by yeast two-hybrid and immunofluorescence, with pathway identification by proteomics and in vivo validation\",\n      \"pmids\": [\"30836961\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"GPER1 mediates estradiol-induced enhancement of hippocampal CA3-CA1 synaptic transmission; G1 pretreatment occludes EB-mediated enhancement, GPER1 antagonist G15 blocks EB-induced synaptic enhancement, and the effect requires ERK activation regardless of ERα or ERβ genotype.\",\n      \"method\": \"Extracellular field potential recordings in hippocampal slices from WT, ERαKO, and ERβKO mice; selective GPER1 agonist G1, antagonist G15, ERK inhibitor, occlusion experiments\",\n      \"journal\": \"Hippocampus\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — electrophysiological recordings with genetic knockout controls and pharmacological dissection, single lab\",\n      \"pmids\": [\"25980457\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"In embryonic hippocampal mHippoE-18 cells, GPER1 activation by 17β-estradiol, G1, tamoxifen, or ICI 182,780 produces dose-dependent potentiation of forskolin-stimulated cAMP (not observed with ERα or ERβ agonists); however, GPER1-specific antagonists G15 and G36 convert agonist-induced cAMP stimulation into inhibition, while aldosterone mimics the antagonist-induced inhibitory effect — consistent with 'biased antagonism' altering receptor coupling.\",\n      \"method\": \"cAMP assay in mHippoE-18 cells (endogenous GPER1), selective ER agonists (PPT for ERα, DPN for ERβ), GPER1 antagonists G15 and G36, aldosterone treatment\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — endogenous receptor in neuronal cell line with pharmacological dissection, single lab, functional cAMP readout\",\n      \"pmids\": [\"26998610\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Insulin transactivates the GPER1 promoter and increases GPER1 mRNA and protein expression through the PRKCD/MAPK1/c-Fos/AP1 transduction pathway in leiomyosarcoma cells and breast cancer-associated fibroblasts; GPER1-dependent cell migration triggered by insulin occurs through GPER1 and its target gene CTGF.\",\n      \"method\": \"GPER1 promoter reporter assay, pharmacological inhibitors of PRKCD and MAPK1, gene silencing, cell migration assays\",\n      \"journal\": \"Endocrine-related cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter reporter assay with pharmacological and siRNA dissection, multiple cancer cell types, single lab\",\n      \"pmids\": [\"25012984\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"In breast cancer cells, 17β-estradiol and GPER1 upregulate ceramide synthases CerS4 and CerS5 via AP-1 transcription factor activation (most likely through dimerization of c-Jun and c-Fos); GPER1 co-transfection enhances CerS2, CerS4, and CerS6 promoter activity.\",\n      \"method\": \"Luciferase reporter gene assays with CerS promoter constructs, promoter deletion and mutation analysis, co-transfection of GPER1, fulvestrant inhibition\",\n      \"journal\": \"Biochemical pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter mutagenesis with luciferase reporters and GPER1 overexpression, single lab\",\n      \"pmids\": [\"25451689\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"GPER1 activation in MCF-7 breast cancer cells mediates 4-OHT (tamoxifen)-induced IGFBP-1 transcription via CREB; extracellular IGFBP-1 then inhibits IGF-1-dependent PI3K/Akt signaling. GPER1 knockdown abrogates 4-OHT-dependent IGFBP-1 induction.\",\n      \"method\": \"Conditioned medium transfer experiments, IGFBP-1 mRNA and protein measurement, GPER1 knockdown, CREB knockdown, phospho-Akt assay, neutralizing antibody experiments\",\n      \"journal\": \"Molecular and cellular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockdown with multiple molecular readouts, single lab\",\n      \"pmids\": [\"26690777\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"GPER-1 activation reduces BBB permeability after global cerebral ischemia by increasing tight junction proteins (occludin and claudin-5) and decreasing VEGF-A expression in the CA1 region.\",\n      \"method\": \"Intracerebroventricular GPER-1 agonist G1 injection in 4-vessel occlusion rat model, IgG extravasation assay, Western blot for tight junctions and VEGF-A\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — pharmacological agonist in vivo with protein expression readouts, no genetic confirmation, single lab\",\n      \"pmids\": [\"27311857\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"GPER1 agonist G-1 attenuates endothelial cell proliferation by inhibiting DNA synthesis and accumulating cells in S and G2 phases; GPER1 siRNA prevents G-1-induced attenuation of DNA synthesis, confirming GPER1 dependence. The antiproliferative effect is independent of ERK/MAP kinase.\",\n      \"method\": \"GPER1 siRNA in bEnd.3 cells, BrdU/DNA synthesis assay, cell cycle analysis, ERK inhibitor PD98059, comparison in COS-7 cells (low GPER1 expression)\",\n      \"journal\": \"Journal of vascular research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA knockdown confirms GPER1 dependence with clear mechanistic readout, multiple endothelial cell types, single lab\",\n      \"pmids\": [\"21273787\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"GPER1 knockdown in gastric cancer cells suppresses proliferation, migration, and invasion by inhibiting PI3K/AKT-mediated EMT; PI3K activator 740Y-P reverses these effects, placing GPER1 upstream of PI3K/AKT in this pathway.\",\n      \"method\": \"siRNA knockdown of GPER1, PI3K activator rescue experiment, EMT marker expression (E-cadherin, N-cadherin, vimentin), transcription factor analysis (Snail, Slug, Twist1), GPER1 overexpression plasmid\",\n      \"journal\": \"Frontiers in cell and developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockdown and overexpression with pharmacological rescue, single lab\",\n      \"pmids\": [\"33425895\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"GPER1 mediates neuroprotection against oxygen-glucose deprivation in hippocampal neurons via PI3K/Akt-dependent Ask1 inhibition; GPER1 knockdown diminishes E2/E2-BSA protection, while GPER1 overexpression potentiates it.\",\n      \"method\": \"GPER1 knockdown and overexpression in primary hippocampal neurons, OGD model, membrane-impermeable E2-BSA, PI3K inhibition, Ask1 phosphorylation assay\",\n      \"journal\": \"Neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic gain and loss of function with pathway identification, single lab\",\n      \"pmids\": [\"27113328\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ERα36 and GPER1 physically interact (by Co-IP) and collaborate to inhibit LPS/TLR4-induced NF-κB activity; GPER1 directly interacts with the p65 component of NF-κB in breast cancer cells. ERα36 knockdown partially inhibits this anti-inflammatory effect in the presence of ERα66.\",\n      \"method\": \"Co-immunoprecipitation of ERα36 with GPER1 and with NF-κB p65, siRNA knockdown, NF-κB reporter assay, IL-6/TNFα expression\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP with functional siRNA knockdown, single lab\",\n      \"pmids\": [\"34299224\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"In human monocytes, GPER1 physically interacts with ERα36 splice variant; ligand-activated ERα36 directly interacts with the p65 component of NF-κB in the nucleus to inhibit IL-6 expression. GPER1 acts as a co-regulator—its inhibition blocks estrogen's anti-IL-6 effect, but GPER1 activation alone does not mimic it.\",\n      \"method\": \"Co-immunoprecipitation of GPER1 with ERα36, nuclear interaction of ERα36 with p65 NF-κB, GPER1/ERα36 selective inhibitors, IL-6 measurement, NF-κB reporter assay in primary human monocytes\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP in primary human cells with functional pharmacological dissection, single lab\",\n      \"pmids\": [\"26394816\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"GPER1 agonist G-1 activates BDNF/TrkB signaling in the hippocampus to improve synaptic and mitochondrial function in SPS (PTSD model) mice; the effect is blocked by both GPER1 antagonist G15 and TrkB inhibitor ANA-12, placing GPER1 upstream of BDNF/TrkB.\",\n      \"method\": \"Western blot and immunofluorescence for GPER1, BDNF/TrkB pathway analysis, electrophysiological LFP recordings, synaptic and mitochondrial protein expression, GPER1 agonist/antagonist in SPS mouse model\",\n      \"journal\": \"CNS neuroscience & therapeutics\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — pharmacological agonism/antagonism approach with pathway analysis, single lab, no genetic confirmation\",\n      \"pmids\": [\"38992889\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"In mucopolysaccharidosis I cells, GPER1 forms aggregates that disappear when cells are treated with the deficient enzyme (which degrades glycosaminoglycans), suggesting GPER1 aggregation is caused by interaction with accumulated GAGs rather than altered protein expression.\",\n      \"method\": \"Immunofluorescence for GPER1 aggregates, enzyme replacement treatment, transcriptomic analysis, GPER1 gene/protein expression comparison between aggregate-positive and negative conditions\",\n      \"journal\": \"European journal of cell biology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — immunofluorescence with enzyme treatment, indirect evidence for GAG-GPER1 interaction, single lab\",\n      \"pmids\": [\"35537249\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"GPER1 activation in macrophages inhibits M1 and M2 macrophage polarization via downregulation of MAPK pathways, reducing renal fibrosis in UUO mice; Gper1 deletion in male UUO mice accelerated fibrosis and increased inflammation.\",\n      \"method\": \"GPER1 agonist G-1 in OVX/male UUO mice, Gper1 knockout mice, RNA-sequencing, immunoblotting for MAPK, macrophage co-culture with tubular epithelial cells and fibroblasts\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockout and pharmacological agonism with RNA-seq pathway analysis, single lab\",\n      \"pmids\": [\"38086848\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"GPER1 activation upregulates the miR-29b oncosuppressor network and blunts an established miR-29b-Sp1 feedback loop in multiple myeloma cells, contributing to anti-tumor activity.\",\n      \"method\": \"GPER1 agonist G-1 in MM cells, miR-29b expression analysis, Sp1 pathway analysis, apoptosis assays, in vivo xenograft models\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — pharmacological approach with miRNA pathway analysis, single lab, mechanistic depth limited\",\n      \"pmids\": [\"37759449\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"In the placenta, E2 enhances melatonin synthetase AANAT expression and melatonin production in primary human trophoblast cells through the GPER1-PKA-CREB signaling pathway.\",\n      \"method\": \"Primary human trophoblast cells, GPER1 pharmacological agonism, PKA and CREB pathway analysis, AANAT expression and melatonin production assays\",\n      \"journal\": \"Journal of pineal research\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — pharmacological approach in primary cells, single lab, no genetic confirmation\",\n      \"pmids\": [\"37746893\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Bisphenol S (BPS)-induced upregulation of Agrp in hypothalamic neurons is prevented by GPER1 inhibitor G15, establishing that BPS acts through GPER1 to induce Agrp expression independently of Atf3 and Klf4 upregulation.\",\n      \"method\": \"GPER1 inhibitor G15 in immortalized murine hypothalamic cell lines (mHypoE-41, mHypoA-59), Agrp mRNA measurement, transcription factor expression profiling\",\n      \"journal\": \"Molecular and cellular endocrinology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — pharmacological inhibition approach only, no genetic confirmation, single lab\",\n      \"pmids\": [\"35569583\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"GPER1 agonist G-1 activates GPER1/cAMP-dependent Erk/MAPK cascade to upregulate Runx2 osteogenic transcription factor in osteoblasts; G15 (GPER1 antagonist) abolishes prunetin-induced increases in cAMP, osteoblast proliferation, and differentiation.\",\n      \"method\": \"Primary rat osteoblast cultures, HEK293T cells, selective GPER1 agonist G-1, antagonist G15, cAMP measurement, ERK/MAPK inhibition, Runx2 expression analysis, in vivo drill-hole injury rat model\",\n      \"journal\": \"The Journal of nutritional biochemistry\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — pharmacological agonism/antagonism, single lab, no genetic confirmation of GPER1 specificity\",\n      \"pmids\": [\"26345541\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"GPER1 (GPR30) is a seven-transmembrane G protein-coupled estrogen receptor that, upon estrogen binding, canonically couples to Gs to stimulate adenylyl cyclase/cAMP, activates Gβγ-dependent transactivation of the EGFR (releasing HB-EGF), and engages Gi/o via a PDZ-motif/AKAP5-dependent constitutive mechanism and a PDZ-independent ligand-stimulated mechanism to increase ERK1/2 activity; a parallel screen study established Gq-phospholipase C-PKC coupling as an additional canonical pathway whose prominence depends on cell-type-specific plasma membrane localization versus endomembrane retention. Downstream, GPER1 signals through PI3K/Akt, MAPK/ERK, and PKA-CREB cascades to regulate diverse processes including synaptic plasticity (via BDNF release and AMPA receptor internalization in hippocampus), vascular tone (via Ca2+ channel inhibition in smooth muscle), immune/inflammatory suppression (by co-regulating NF-κB with ERα36), ERα protein stability (by upregulating the E3 ubiquitin ligase adaptor SPOP), MORC2 stability (via PRKACA-dependent phosphorylation that blocks chaperone-mediated autophagy), type I interferon signaling suppression in fetal tissues, and aldosterone synthesis (via PKA signaling in adrenocortical cells).\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"GPER1 (GPR30) is a seven-transmembrane G protein-coupled estrogen receptor that translates estrogen binding into rapid non-genomic signaling to regulate vascular, neuronal, reproductive, immune, and oncogenic processes [#0, #14]. As a Gs-coupled receptor it stimulates adenylyl cyclase and drives Gβγ-dependent release of membrane-tethered HB-EGF, transactivating the EGFR [#0]; in parallel it engages Gi/o to increase ERK1/2 activity through both a constitutive PDZ-motif/AKAP5-anchored mechanism and a ligand-stimulated PDZ-independent mechanism, with the PDZ interaction (SAP97, AKAP5) anchoring the receptor at the plasma membrane and constitutively lowering cAMP [#1], and it couples to a Gq–phospholipase C–PKC–ERK cascade whose prominence tracks with cell-type-specific plasma-membrane versus endomembrane localization [#2]. Downstream, GPER1 signals through PKA, PI3K/Akt, and MAPK/ERK to diverse effectors: it activates PRKACA to phosphorylate MORC2 at Thr582, blocking its chaperone-mediated autophagic degradation [#3], and upregulates the Cullin3 E3 ligase adaptor SPOP to drive ubiquitin-proteasomal degradation of ERα, restraining estrogen-driven breast cancer growth [#6]. In the nervous system it triggers hippocampal BDNF release with Arc translation and AMPA-receptor (GluA1) internalization underlying synaptic plasticity [#4] and mediates estradiol-induced potentiation of CA3–CA1 transmission via ERK [#18]. In the vasculature it controls tone through EGFR/Src/Akt-dependent vasorelaxation and L-type Ca2+ channel inhibition in smooth muscle [#10, #11]. GPER1 also suppresses inflammatory signaling—co-regulating NF-κB with ERα36 and interacting with p65 [#27, #28]—and, genetically, is a required suppressor of type I interferon signaling protecting fetal development under maternal inflammation [#14]. Additional aldosterone, angiogenic, and matrix-assembly roles connect the receptor to adrenocortical PKA signaling, glycolytic PFKFB3, and integrin α5β1–Shc adhesion complexes [#5, #8, #7].\",\n  \"teleology\": [\n    {\n      \"year\": 2012,\n      \"claim\": \"Established that GPER1 is a bona fide membrane estrogen receptor pharmacologically distinct from nuclear ERs, defining its core Gs/cAMP and EGFR-transactivation output.\",\n      \"evidence\": \"Pharmacological agonist/antagonist dissection, receptor knockdown, and cAMP assays\",\n      \"pmids\": [\"22495674\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve which G proteins dominate in different cell types\", \"No structural basis for ligand discrimination\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Resolved how GPER1 controls ERK1/2, distinguishing a constitutive PDZ/AKAP5-anchored route from a ligand-stimulated PDZ-independent route and linking receptor anchoring to cAMP regulation.\",\n      \"evidence\": \"PDZ-motif deletion mutants, AKAP5 knockdown, pertussis toxin and kinase/phosphatase inhibitors with ERK1/2 assays\",\n      \"pmids\": [\"28450397\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological relevance of constitutive vs. ligand-driven signaling in vivo not defined\", \"Whether the two mechanisms act in the same cells unclear\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Demonstrated Gq–PLC–PKC–ERK coupling and showed that subcellular localization (plasma membrane vs. endomembrane) reconciles contradictory signaling reports across cell lines.\",\n      \"evidence\": \"Multiplexed GPCR Ca2+ screen, Gq inhibitor YM-254890, internalization and localization imaging across multiple cell lines\",\n      \"pmids\": [\"36400433\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Failure to reproduce cAMP increases leaves Gs coupling context-dependent and unresolved\", \"Determinants of plasma-membrane versus endomembrane targeting unidentified\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Connected GPER1 to synaptic plasticity by showing it drives BDNF release, Arc translation, and AMPA receptor internalization, providing a mechanism for estrogen modulation of hippocampal function.\",\n      \"evidence\": \"GPER1 agonist G1, BDNF/Arc/GluA1 assays, proteasome inhibition, and hippocampal slice electrophysiology\",\n      \"pmids\": [\"26391661\", \"25980457\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endogenous estrogen ligand source in this circuit not established\", \"Receptor localization (pre- vs. postsynaptic) not defined\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identified a GPER1→PRKACA→MORC2 phosphorylation axis that stabilizes MORC2 by blocking chaperone-mediated autophagy, linking the receptor to antiestrogen resistance.\",\n      \"evidence\": \"Co-IP, T582A phospho-site mutagenesis, CMA pathway inhibition, and knockdown/rescue in breast cancer cells\",\n      \"pmids\": [\"32401166\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct kinase–substrate contact not structurally resolved\", \"Generality beyond breast cancer cells untested\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Showed GPER1 negatively regulates ERα protein via SPOP-mediated ubiquitin-proteasomal degradation, establishing a tumor-suppressive cross-talk with the nuclear estrogen pathway.\",\n      \"evidence\": \"Co-IP, ubiquitination assay, SPOP knockdown rescue, proteasome inhibition, and xenograft validation\",\n      \"pmids\": [\"33069770\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signaling steps linking GPER1 activation to SPOP upregulation not mapped\", \"Whether SPOP induction is transcriptional or post-translational unclear\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Genetic knockout established GPER1 as a necessary suppressor of type I interferon signaling that protects fetal development during maternal inflammation.\",\n      \"evidence\": \"GPER1 knockout mice, maternal inflammation models, and tissue-specific IFN signaling comparison\",\n      \"pmids\": [\"33446553\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular link between GPER1 and IFN pathway components not defined\", \"Cell type mediating tissue-selective suppression unidentified\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Extended GPER1 outputs to steroidogenesis and matrix biology, showing PKA-driven aldosterone synthase induction and integrin α5β1–Shc–dependent fibronectin assembly.\",\n      \"evidence\": \"Agonist/antagonist plus gene silencing for aldosterone (HAC15 cells) and Shc Y317F mutagenesis with adhesion/haptotaxis assays\",\n      \"pmids\": [\"25167221\", \"25096985\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab findings for each role\", \"Interplay with ERβ in steroidogenic regulation only partially mapped\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Defined GPER1 control of vascular tone through EGFR/Src/Akt-dependent vasorelaxation and L-type Ca2+ channel inhibition in smooth muscle.\",\n      \"evidence\": \"Ex vivo aortic/renal preparations and A7r5 Ca2+ imaging with selective kinase and channel inhibitors plus GPER1 antagonists\",\n      \"pmids\": [\"24028616\", \"24080531\", \"23376418\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Pharmacology-only dissection without genetic confirmation in vessels\", \"Reconciliation of vasoconstrictor versus vasodilator effects across beds incomplete\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Implicated GPER1 in inflammatory suppression via physical partnership with ERα36 and direct interaction with NF-κB p65 to inhibit TLR4-driven cytokine production.\",\n      \"evidence\": \"Co-IP of GPER1 with ERα36 and p65, siRNA knockdown, and NF-κB reporter/cytokine assays in breast cancer cells and monocytes\",\n      \"pmids\": [\"34299224\", \"26394816\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Reciprocal/structural validation of the GPER1–p65 interaction lacking\", \"Whether GPER1 acts at the membrane or nucleus in this complex unclear\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identified autocrine motility factor as a direct GPER1-binding partner that co-translocates and activates PI3K/AKT to promote cancer cell growth.\",\n      \"evidence\": \"Yeast two-hybrid, Co-IP, immunofluorescence, iTRAQ proteomics, and xenograft model in endometrial cancer cells\",\n      \"pmids\": [\"30836961\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Binding interface and stoichiometry undefined\", \"Physiological relevance outside cancer context untested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How cell-type-specific localization and ligand identity dictate the choice among Gs, Gi/o, and Gq outputs, and the structural basis of GPER1 ligand recognition, remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model of ligand-bound GPER1 in the corpus\", \"Determinants of plasma-membrane vs. endomembrane retention unknown\", \"In vivo dominance of each G-protein pathway not established\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 2, 18]},\n      {\"term_id\": \"GO:0001618\", \"supporting_discovery_ids\": []},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [27, 28]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [1, 2]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [2]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1, 2]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [14, 27, 28]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [3, 6]},\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [4, 18]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"AKAP5\", \"SAP97\", \"ERa36\", \"RELA\", \"AMF\", \"EGFR\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}